fr

touchpodcast

touchPODCAST

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005!We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updatesHome...

N'hésitez pas à visiter le site du podcast et à soutenir son créateur : touchpodcast.podbean.com

Auteur

touchpodcast

Catégorie

Science

Site du podcast

touchpodcast.podbean.com

Dernier épisode

15 oct. 2026

Où écouter ?

Les podcasts dans l'appli Replaio Radio Bientôt disponible

Les podcasts arrivent très bientôt dans l'appli. Installe-la dès maintenant et découvre en avant-première une toute nouvelle façon de vivre les podcasts

Télécharger sur Google Play Installe-la gratuitement Android près de 10 M de téléchargements · note de 4,8 iOS bientôt

Épisodes

Primary biliary cholangitis: Appraising the changing therapeutic landscape 14.11.2024

touchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis.  The expert Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is join...

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 14.11.2024

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pha...

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 14.11.2024

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pha...

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 14.11.2024

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology...

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 14.11.2024

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology...

touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 13.11.2024

touchMDT for touchRESPIRATORY What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible imm...

touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13.11.2024

touchMDT for touchRESPIRATORY What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights. The multidisciplinary team Medical oncologist – Dr Ja...

touchMDT for touchRESPIRATORY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? 13.11.2024

touchMDT for touchRESPIRATORY What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-S...

touchMDT for touchONCOLOGY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 13.11.2024

touchMDT for touchONCOLOGY What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune...

touchMDT for touchONCOLOGY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13.11.2024

touchMDT for touchONCOLOGY What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights. The multidisciplinary team Medical oncologist – Dr Jacob...

touchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? 13.11.2024

touchMDT for touchONCOLOGY What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC...

Vaccination strategies for pneumococcal disease 05.11.2024

touchEXPERT OPINIONS for touchINFECTIOUS DISEASES In this activity, Prof. Antoni Torres, a leading expert in respiratory infections, discusses the burden of pneumococcal disease in vulnerable patient populations, the evolving landscape of Streptococcus pneumoniae subtypes and the role that next-generation vaccines can play in preventing severe pneumococcal infections. The expert Prof. Antoni Torre...

Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024 28.10.2024

touchCONGRESS for touchONCOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr...

Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024 28.10.2024

touchCONGRESS for touchHAEMATOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and...

Pharmacological management of agitation in Alzheimer's dementia 24.10.2024

touchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of leading experts discuss best practice in the management of agitation in Alzheimer’s dementia and the potential of new pharmacological approaches that target aspects of the underlying pathophysiology.  The experts Prof. Jeffrey Cummings, University of Nevada, Las Vegas, NV, USA  Prof. Krista Lanctôt, University of Toronto, ON, Canada  Pr...

touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchRESPIRATORY 24.10.2024

touchIN CONVERSATION for touchRESPIRATORY Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support...

touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchCARDIO 24.10.2024

touchIN CONVERSATION for touchCARDIO Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support trea...

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1 16.10.2024

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pha...

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2 16.10.2024

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pha...

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1 16.10.2024

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology...

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2 16.10.2024

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology...

Targets in early NSCLC: A focus on EGFR-mutant treatment options 15.10.2024

touchFOCUS for touchONCOLOGY Listen to Dr Jennifer Carlisle, an expert in lung cancer, as she answers a series of questions on the targeted perioperative treatment strategies and best practices for patients with resectable and unresectable early-stage EGFR-mutant NSCLC. She also discusses how the evolving treatment landscape impacts biomarker testing and the importance of multidisciplinary care fo...

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024 07.10.2024

touchCONGRESS for touchONCOLOGY Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to disc...

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024 07.10.2024

touchCONGRESS for touchHAEMATOLOGY Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to d...

Innovations in glaucoma care: Targeting pathophysiology to expand treatment options 07.10.2024

touchEXPERT OPINIONS for touchOPHTHALMOLOGY Listen to leading experts describe the pathophysiology of open-angle glaucoma and discuss how it is targeted by current and emerging treatment options, while providing insights on how different agents and combinations are used in practice. The experts Angelo P Tanna, MD - Northwestern University Feinberg School of Medicine, Chicago, IL, USA Courtney E Bo...

Écoute le podcast touchPODCAST sur Replaio

La radio et les podcasts dans une seule appli - gratuite, sans inscription. Installe-la dès aujourd'hui et ne rate pas le lancement

Télécharger sur Google Play

Replaio n'est pas éditeur de podcasts ; les noms des émissions, les visuels et l'audio appartiennent à leurs auteurs et sont diffusés via des flux RSS publics